PET/MR Imaging for Kidney Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a special imaging technique called PET/MR can better identify different types of kidney tumors. Many kidney tumors discovered incidentally during scans for other issues are not cancerous, yet they often lead to unnecessary treatments. The trial seeks to determine if PET/MR can distinguish between aggressive tumors that might spread and those that are harmless or slow-growing. Individuals who might be suitable for this trial have a suspicious kidney mass and are already scheduled for an MRI. Participants will receive a PET/MR scan and might be contacted for follow-ups to monitor health changes over time.
As a Phase 2 trial, this research focuses on measuring how well PET/MR works in an initial, smaller group of people, offering participants a chance to contribute to advancements in kidney tumor diagnosis.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It seems likely that you can continue them, but it's best to confirm with the study team.
What prior data suggests that this PET/MR technique is safe for assessing kidney tumors?
Research has shown that Fludeoxyglucose (FDG) F 18 has been tested in many patients and is generally well-tolerated. In studies involving 374 people, the treatment did not cause significant side effects. The main issue reported was mild irritation at the injection site, which is rare. FDG, a type of radioactive sugar, is used in imaging tests to help find tumors. The FDA has already approved it for other uses, indicating its safety for humans. Overall, evidence suggests that FDG is safe and causes few problems when administered to patients.12345
Why are researchers excited about this trial?
Researchers are excited about using PET/MRI for characterizing renal masses because it combines the strengths of two powerful imaging techniques. Unlike standard imaging options, such as CT or ultrasound, PET/MRI offers detailed anatomical and metabolic information in one go. This means it can more accurately distinguish between benign and malignant tumors, potentially reducing the need for invasive biopsies. The hope is that this method will lead to more precise diagnoses and better treatment planning for patients with renal masses.
What evidence suggests that this PET/MR technique is effective for distinguishing kidney tumors?
Studies have shown that FDG PET scans can accurately differentiate between types of kidney masses. In one study, FDG-PET correctly identified 23 out of 27 kidney tumors as either non-cancerous or cancerous. Another study found that FDG PET/CT scans effectively distinguish cancerous kidney masses from non-cancerous ones by analyzing their energy usage. This trial will observe patients diagnosed with incidental solid renal masses using FDG PET/MR, potentially helping doctors determine if a kidney mass is dangerous. This improved imaging technique might reduce unnecessary surgeries for non-cancerous or less aggressive kidney masses.678910
Who Is on the Research Team?
Ivan Pedrosa, MD, PhD
Principal Investigator
University of Texas Southwestern Medical Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Data Collection
Participants undergo a PET/MR scan to assess kidney tumors, including administration of FDG and furosemide
Follow-up
Participants are monitored for health updates and changes in diagnosis through periodic phone calls
What Are the Treatments Tested in This Trial?
Interventions
- 2-Deoxy-2-[18F]fluoroglucose
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All patients at our institution who are diagnosed with indeterminate solid SRM and without prior treatment for the tumor, renal biopsy or contraindication to PET/MRI can be included in the study. This will be a prospective, non-randomized, non-blinded observational study. Patients will then be managed following the standard of care.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
Radiological Society of North America
Collaborator
Citations
2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission ...
Results: Of the 28 solid renal masses, 10 were primary (nine malignant, one benign) and 18 were metastatic renal tumors. FDG-PET accurately depicted 23 of 27 ( ...
Utility of Fluorine18 Fluoro-2-deoxy-D-glucose Positron ...
F18-FDG PET/CT can efficiently characterize solid renal mass lesion as benign and malignant using metabolic parameters such as max.SUV and RI.
FDG PET characterization of renal masses: Preliminary ...
This study was undertaken to evaluate the potential efficacy of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) to detect renal ...
The Place of FDG PET/CT in Renal Cell Carcinoma
18F-fluoro-2-deoxy-2-d-glucose (FDG) PET seems useful for postoperative surveillance in patients with RCC. It can detect recurrence in the surgical site.
A prospective diagnostic accuracy study of F-18 ...
The results of previous studies made to assess the efficacy of F-18 FDG PET in the evaluation of renal masses are summarized in Table 2. Summary of previous ...
Fludeoxyglucose F 18 Injection - accessdata.fda.gov
Fludeoxyglucose F 18 Injection is provided as a ready to use isotonic, sterile, pyrogen free, clear, colorless citrate buffered solution.
SAFETY DATA SHEET Potential Health Effects
No adverse effect expected, but may cause mechanical irritation. COMPONENTS. CONCENTRATION. CAS NO. 2-Fluoro-2-deoxy-D-glucose. <0.001%.
8.
dailymed.nlm.nih.gov
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eb82924-1ce4-680e-e054-00144ff88e88fludeoxyglucose f-18 injection injection - DailyMed - NIH
It is administered by intravenous injection. The active ingredient 2-deoxy-2-[ 18 ... The [ 18F]FDG safety data base was evaluated for 374 patients. Of these, 245 ...
Fludeoxyglucose F 18 Injection (FDG): Side Effects, Uses, ...
The [18F]FDG safety data base was evaluated for 374 patients. Of ... Estimated Absorbed Radiation Doses after intravenous administration of 2-deoxy-2-[18F ...
Fludeoxyglucose (18F): Uses, Interactions, Mechanism of ...
[18F]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[18F] fluoro-6 ... View sample adverse effects data in our new Data Library! See the data.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.